Source
From GlobeNewswire
2 releases originally issued via GlobeNewswire. The issuing organizations are responsible for their content.
Climb Bio, Inc.
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data;…